Dawson James Securities launched coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and price target of $19. The stock closed at $6.51 on Aug. 23. “Creating a launch pad for biotechnology assets, Fortress...
Tag - Fortress Biotech
